Unlock instant, AI-driven research and patent intelligence for your innovation.

GATA-2 mutator as one of leukemia rapid change major genes and its use

A GATA-2, mutation gene technology, applied in the fields of application, gene therapy, genetic engineering, etc., can solve the problems of few reports, no GATA-2 mutation and chronic myelogenous leukemia blast

Inactive Publication Date: 2007-11-07
RUIJIN HOSPITAL ATTACHED TO SHANGHAI NO 2 MEDICALUNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the research on GATA-2 mainly focuses on its biological characteristics and functions, but there are few reports on its role in leukemia, and there are no reports on the correlation between GATA-2 mutations and chronic myeloid leukemia blast

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • GATA-2 mutator as one of leukemia rapid change major genes and its use
  • GATA-2 mutator as one of leukemia rapid change major genes and its use
  • GATA-2 mutator as one of leukemia rapid change major genes and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] PCR amplification of each exon of GATA-2 gene

[0061] 1. Patient sample collection and processing: Collect 5-10ml of the patient's bone marrow before treatment begins, anticoagulate with heparin, separate mononuclear cells by density gradient centrifugation on the same day, add appropriate amount of white blood cell lysate and proteinase K, and wait for the white blood cells to be fully lysed Genomic DNA was extracted by the phenol-chloroform method and stored at -20°C for later use. Total RNA extraction and cDNA synthesis: Total RNA extraction and reverse transcription were carried out according to the standard operating procedures of the kit (GIBCO BRL Company).

[0062] Normal control: 5ml of peripheral blood from employees whose annual physical examination indicators were normal in Ruijin Hospital, a total of 200 copies. DNA was prepared as previously described.

[0063] 2. Primer design: The software Primer premier 5 was used, and the primer parameters were set ...

Embodiment 2

[0067] PCR product purification and sequencing:

[0068] 1. PCR product purification Use Shrimp Alkaline Phosphatase (SAP) and exonuclease (Exonuclease I) to purify the PCR product, the reaction system is: SAP 0.16 μl, Exonuclease I 0.25 μl, PCR product 50ng, add water to make up to the total volume 7μl; purification reaction program: 37°C for 60min, 80°C for 15min, 4°C forver.

[0069] 2. ABI 3700 Automatic Sequencer (PEBiosystems) was used for the sequencing of PCR purified products. Sequence the PCR fragments

[0070] 1) Take out the PCR purified product, MIX, and 0.8uM primers from the refrigerator at -20°C

[0071] 2) Take a 96-well reaction plate, mark the name of the template (that is, the name of the PCR purified product) and the date, add 2 ul of primers one by one with a continuous sampler, then add 2 ul of the template with a 12-hole row gun, and finally add mix one by one with a continuous sampler Shake 2ul on the centrifuge and stop when it reaches about 1300 r...

Embodiment 3

[0081] Search for mutation sites:

[0082] Polyphred software was used to search for mutation sites. The Polyphred software will mark suspicious mutation sites with various colors, and different colors represent different degrees of confidence. The final confirmation needs to be evaluated with the naked eye by opening the graphics. For mutation sites with high abundance, the reliability of software identification is very high, but for mutation sites with low abundance, if only one sample shows a heterozygous pattern, it needs to be determined with the naked eye based on the evaluation criteria to remove the Bad interference. To judge whether a site is a mutation site, at least the following conditions should be met: 1) It shows that the sequences on both sides of the heterozygous base are identifiable single peaks, and the background is relatively low; 3) Comparing the sequencing graphs of heterozygous individuals and homozygous individuals, the base peaks in the graphs of h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to GATA-2 mutator as one of rapid change major genes of chronic granulocyte leukemia and its application, and the GATA-2 mutator detecting kit and its use. The present invention associates GATA-2 mutator with the medicine treatment of chronic granulocyte leukemia patient, so that medicine acting on these target points may be developed to treat chronic granulocyte leukemia. The present invention provides theoretic basis for developing new medicine to treat the rapid change patient of chronic granulocyte leukemia.

Description

technical field [0001] The invention relates to the fields of molecular genetics, cell biology and leukemia. Specifically, the present invention relates to the GATA-2 mutant gene and its application Background technique [0002] Chronic myelogenous leukemia (CML) is a proliferative disorder of hematopoietic stem cells, characterized by the Philadelphia chromosome translocation t(9;22)(q34;q11). The BCR-ABL fusion protein produced by the translocation has persistent tyrosine kinase activity, which can transform cells and lead to tumorigenesis. Experiments on transgenic mice have confirmed that BCR-ABL fusion protein can lead to the occurrence of chronic myelogenous leukemia, allowing cells to gain survival and proliferation advantages. However, when chronic myelogenous leukemia blasts, cells will also undergo differentiation arrest. Therefore, clinically, CML patients need a "second hit" to transform from the relatively benign chronic phase to the accelerated phase and the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/12C12Q1/68A61K48/00A61P35/00
Inventor 陈竺陈赛娟张苏江顾柏炜施静艺李国高晓东
Owner RUIJIN HOSPITAL ATTACHED TO SHANGHAI NO 2 MEDICALUNIV